| Literature DB >> 30120309 |
Gang Huang1,2, Rong-Hua Xu3, Jun-Bo Xu3,4, Ya Liu3, Zhao-Hui Liu3, Xue Xie3, Ting-Jie Zhang5.
Abstract
Hyperuricemia is a risk factor for cardiovascular diseases. However, in very elderly, the relationship between hyperuricemia and the prevalence of atrial fibrillation (AF) is not clear. This study aimed to investigate hyperuricemia and the risk of AF in community very elderly. In this cross-sectional study, 1056 very elderly in community were enrolled. Serum uric acid (SUA) were measured and rest 12-lead electrocardiogram was performed. Multiple logistic regression models were used to explore risk factors for AF in very elderly. Finally, 1038 participants were included in analysis and the mean age of the study participants were 83.6 ± 3.4 years (age range 80-100 years). The mean SUA level was 350.1 ± 84.5 µmol/L. The estimated prevalence of AF was 5.3%, and there was no significant sex difference (5.8% for men and 4.8% for women, p = 0.401). Multiple logistic regression found that participants with hyperuricemia (SUA >416 µmol/L in men and >357 µmol/L in women) had a higher risk (odds ratio: 2.080, 95% confidence interval: 1.103-4.202, P = 0.007) of suffering AF in very elderly Chinese. In conclusion, AF is relatively frequent in this community very elderly Chinese in Chengdu. Hyperuricemia is associated with the prevalence of AF in general very elderly.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30120309 PMCID: PMC6098088 DOI: 10.1038/s41598-018-30321-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of Participants.
| Total n = 1038 | AF n = 55 | Non AF n = 983 | p value | |
|---|---|---|---|---|
| Age (years) | 83.6 ± 3.4 | 83.9 ± 3.6 | 83.6 ± 3.4 | 0.552 |
| Current smoker, %(n) | 11.1 (115) | 5.5 (3) | 11.4 (112) | 0.173 |
| Current drinker, %(n) | 8.3 (86) | 14.5 (8) | 8.0 (78) | 0.125 |
| Medical history, %(n) | ||||
| Hypertension | 52.6 (546) | 56.4 (31) | 52.4 (515) | 0.566 |
| DM | 12.3 (128) | 9.1 (5) | 12.5 (123) | 0.453 |
| Stroke | 8.8 (91) | 5.5 (3) | 9.0 (88) | 0.470 |
| MI | 7.2 (75) | 7.3 (4) | 7.2 (71) | 0.989 |
| Medication %(n) | ||||
| ACEI/ARB | 11.9 (124) | 12.7 (7) | 11.9 (117) | 0.854 |
| CCB | 26.1 (271) | 34.5 (19) | 25.6 (252) | 0.143 |
| β-receptor blocker | 7.8 (81) | 20.0 (11) | 7.1 (70) | 0.002 |
| Diuretics | 6.6 (68) | 3.6 (2) | 6.7 (66) | 0.574 |
| BMI (kg/m2) | 23.1 ± 3.7 | 23.7 ± 4.1 | 23.1 ± 3.7 | 0.282 |
| SBP (mmHg) | 146.4 ± 20.6 | 145.4 ± 21.0 | 146.6 ± 22.4 | 0.830 |
| DBP (mmHg) | 74.1 ± 11.9 | 82.5 ± 14.9 | 73.7 ± 11.7 | <0.001 |
| PP (mmHg) | 72.5 ± 17.1 | 63.9 ± 16.1 | 73.6 ± 18.2 | <0.001 |
| Heart rate (bpm) | 70.0 ± 9.0 | 72.0 ± 14.9 | 69.5 ± 7.6 | 0.005 |
| FBG (mmol/L) | 5.53 ± 1.35 | 5.37 ± 1.19 | 5.55 ± 1.38 | 0.081 |
| TC (mmol/L) | 4.87 ± 0.99 | 4.46 ± 0.97 | 4.89 ± 0.98 | 0.001 |
| TG (mmol/L) | 1.34 ± 0.57 | 1.15 ± 0.51 | 1.37 ± 0.80 | 0.020 |
| LDL-C (mmol/L) | 2.58 ± 0.74 | 2.27 ± 0.70 | 2.60 ± 0.74 | 0.001 |
| SUA (µmol/L) | 350.1 ± 84.5 | 382.3 ± 94.0 | 348.9 ± 89.6 | 0.005 |
| Creatinine, μmol/L | 104.1 ± 32.4 | 110.2 ± 27.8 | 103.9 ± 33.0 | 0.008 |
| e GFR, ml/(min∙1.73 m2) | 58.7 ± 13.9 | 55.3 ± 13.5 | 58.6 ± 13.9 | 0.084 |
Data are presented as mean ± standard deviation or Percentage(number). P value from comparison between AF group and non AF group. ACEI indicates angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blockers; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate, FBG, fasting blood glucose; LDL-C, Low-density lipoprotein cholesterol; MI, myocardial infarction; PP, pulse pressure; SBP, systolic blood pressure; SUA, serum uric acid; TC, total cholesterol; TG, triglycerides. eGFR was calculated according to Cockcroft-Gault equation.
Prevalence of AF.
| Prevalence of AF, %(n) | ||||
|---|---|---|---|---|
| Total | Men | Women | p value | |
| Total | 5.3 (55) | 5.8 (30) | 4.8 (25) | 0.401 |
| Age 80–84 | 4.7 (34) | 5.8 (21) | 3.6 (13) | 0.146 |
| 85–89 | 6.9 (17) | 5.6 (7) | 8.2 (10) | 0.552 |
| ≥90 | 5.8 (4) | 6.3 (2) | 5.4 (2) | 0.976 |
| Participants with | ||||
| Hypertension | 5.9 (47) | 7.2 (28) | 4.7 (19) | 0.137 |
| New hypertension | 6.0 (15) | 7.7 (10) | 4.1 (5) | 0.234 |
| Self reported hypertension | 5.9 (32) | 6.9 (18) | 4.9 (14) | 0.324 |
| Prehypertension | 2.9 (5) | 2.4 (2) | 3.3 (3) | 0.717 |
| Normotension | 4.4 (3) | 4.7 (2) | 4.0 (1) | 0.900 |
| DM | 5.7 (12) | 6.3 (7) | 5.1 (5) | 0.709 |
| New DM | 8.6 (5) | 10.8 (4) | 5.6 (1) | 0.658 |
| Self reported DM | 4.6 (7) | 4.1 (3) | 5.0 (4) | 0.778 |
| IFG | 3.0 (2) | 5.1 (2) | 0 | 0.509 |
| NFG | 5.4 (41) | 6.3 (23) | 4.5 (18) | 0.292 |
| Obesity | 10.3 (10) | 14.6 (6) | 7.1 (4) | 0.314 |
| Non-obesity | 4.8 (45) | 5.5 (26) | 4.1 (19) | 0.323 |
| Hyperuricemia | 7.6 (26) | 10.3 (16) | 5.4 (10) | 0.108 |
| Non-hyperuricemia | 4.2 (29) | 4.4 (16) | 3.9 (13) | 0.716 |
Percentages represent the number with atrial fibrillation/total population. P value are from comparison between men and women. AF indicates atrial fibrillation; DM, diabetes mellitus; IFG, impaired fasting glucose; NFG, normal fasting glucose.
Multiple logistic regression analysis of risk factors for AF in total and subgroups.
| Total | Hypertension | DM | |
|---|---|---|---|
| Age (years) | |||
| 80–84 | Ref. | Ref. | Ref. |
| 85–89 | 1.971 (0.995–3.860) | 2.842 (1.363–6.573)* | 3.062 (0.484–20.013) |
| ≥90 | 2.026 (0.646–6.248) | 4.153 (1.148–13.462)* | 0.000 |
| Sex | |||
| Men | Ref. | Ref. | Ref. |
| Women | 0.706 (0.357–1.270) | 0.701 (0.335–1.417) | 0.524 (0.101–3.362) |
| Smoking | |||
| No | Ref. | Ref. | Ref. |
| Yes | 0.344 (0.102–1.465) | 0.421 (0.11–1.825) | 1.040 (0.072–17.234) |
| Obesity | |||
| No | Ref. | Ref. | Ref. |
| Yes | 2.502 (1.114–6.041)* | 3.032 (1.115–6.371)* | 3.53 (0.392–30.348) |
| Hypertension | |||
| No | Ref. | — | Ref. |
| Yes | 3.637 (1.385–9.325)* | 3.317 (0.279–45.436) | |
| PP (mmHg) | |||
| <60 | Ref. | Ref. | Ref. |
| 60–79 | 0.301 (0.125–0.652)* | 0.232 (0.108–0.552)* | 0.503 (0.084–3.013) |
| ≥80 | 0.115 (0.047–0.314)* | 0.101 (0.041–0.266)* | 0.000 |
| DM | |||
| No | Ref. | Ref. | — |
| Yes | 0.725 (0.323–1.561) | 0.716 (0.301–1.622) | |
| Hyperuricemia | |||
| No | Ref. | Ref. | Ref. |
| Yes | 2.080 (1.103–4.202)* | 2.452 (1.230–5.238)* | 10.254 (1.350–67.137)* |
| TG > 1.7 mmol/L | |||
| No | Ref. | Ref. | Ref. |
| Yes | 0.339 (0.114–1.068) | 0.416 (0.128–1.405) | 0.231 (0.033–3.262) |
| TC > 5.2 mmol/L | |||
| No | Ref. | Ref. | Ref. |
| Yes | 0.452 (0.200–1.102) | 0.395 (0.160–1.315) | 0.213 (0.025–3.325) |
| e GFR ≤ 60 ml/(min∙1.73 m2) | |||
| No | Ref. | Ref. | Ref. |
| Yes | 2.576 (1.370–6.038)* | 3.402 (1.415–8.328)* | 2.732 (1.248–16.348)* |
All models included age, sex, smoking, obesity, hypertension, DM, PP, TG, TC, e GFR and hyperuricemia. *P <0.05 versus reference category. AF indicates atrial fibrillation; DM, diabetes mellitus; e GFR,estimated glomerular filtration rate; PP, pulse pressure; TC, total cholesterol; TG, triglycerides.